FreshPatents.com Logo


new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc_20100128
Regeneron Pharmaceuticals Inc_20131212

Popular
Companies


Web
Adobe patents
Akamai patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Ticker Symbols

Regeneron Pharmaceuticals, Inc. patents


      
Recent patent applications related to Regeneron Pharmaceuticals, Inc.. Regeneron Pharmaceuticals, Inc. is listed as an Agent/Assignee. Note: Regeneron Pharmaceuticals, Inc. may have other listings under different names/spellings. We're not affiliated with Regeneron Pharmaceuticals, Inc., we're just tracking patents.

ARCHIVE: New 2014 2013 2012 2011 2010 2009 | Company Directory "R" | Regeneron Pharmaceuticals, Inc.-related inventors



Search recent Press Releases: Regeneron Pharmaceuticals, Inc.-related press releases
Count Application # Date Regeneron Pharmaceuticals, Inc. patents (updated weekly) - BOOKMARK this page
12014035637012/04/14Methods for treating autosomal dominant hypercholesterolemia associated with pcsk9 gain-of-function mutations
22014035637112/04/14Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
32014035637212/04/14Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
42014033134011/06/14Methods and compositions for generating a mouse
52014032221510/30/14Methods of inhibiting tumor growth by antagonizing il-6 receptor
62014031524910/23/14Inducible eukaryotic expression system
72014028987609/25/14Mice that make heavy chain antibodies
82014027164209/18/14Il-33 antagonists and uses thereof
92014027165309/18/14Human antibodies to respiratory syncytial virus f protein and methods of use thereof
102014027165809/18/14Anti-il-33 antibodies and uses thereof
112014027168109/18/14High affinity human antibodies to human il-4 receptor
122014027309509/18/14Serum-free cell culture medium
132014027548909/18/14Apelin fusion proteins and uses thereof
142014028315809/18/14Rodents with conditional acvr1 mutant alleles
152014025539009/11/14Method of treating rheumatoid arthritis with an anti-il-6r antibody
162014025541909/11/14Method of treating stress hyperglycemia with human antibodies to the glucagon receptor
172014025542909/11/14Methods of treating autoimmune diseases with dll4 antagonists
182014025599509/11/14High affinity antibodies to human il-6 receptor
192014024866409/04/14Readily isolated bispecific antibodies with native immunoglobulin format
202014024350408/28/14Antibodies comprising chimeric constant domains
212014024546608/28/14Humanized t cell co-receptor mice
222014024546708/28/14Genetically modified major histocompatibility complex mice
232014024546808/28/14Non-human animals with modified immunoglobulin heavy chain sequences
242014022002308/07/14Method of treating osteoarthritis with an antibody to ngf
252014021377307/31/14Adam6 mice
262014019655007/17/14Systems and devices for sample handling
272014019976107/17/14Promoter-regulated differentiation-dependent self-deleting cassette
282014019340207/10/14Anti-pdgfr-beta antibodies and uses thereof
292014019459707/10/14Modified chimeric polypeptides with improved pharmacokinetic properties
302014018990007/03/14Mirna-regulated differentiation-dependent self-deleting cassette
312014017887906/26/14Compositions and methods for modifying cells
322014017990306/26/14High affinity human antibodies to human protease-activated receptor 2
332014015470106/05/14Humanized fc gamma r mice
342014015568906/05/14Methods of modifying genes in eukaryotic cells
352014015744506/05/14Low affinity fcgr deficient mice
362014013797805/22/14System and methods for use in dispensing biopharmaceutical materials
372014013416905/15/14Methods of treating ovarian cancer with dll4 antagonists
382014013418905/15/14Anti-prokineticin receptor (prokr) antibodies and uses thereof
392014013471905/15/14Recombinant cell surface capture proteins
402014013727505/15/14Hybrid light chain mice
412014013019305/08/14Mice that make vl binding proteins
422014013019405/08/14Mice that make vl binding proteins
432014012010905/01/14Human antibodies to human tnf-like ligand 1a (tl1a)
442014011293004/24/14Methods for treating or preventing malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
452014009931204/10/14Methods for treating hypercholesterolemia and reducing ldl-c using antibodies to pcsk9
462014008829503/27/14Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
472014008276003/20/14Non-human animals expressing ph-sensitive immunoglobulin sequences
482014007256303/13/14Methods and compositions comprising a combination of an anti-erbb3 antibody and an anti-egfr antibody
492014007258303/13/14Methods for treating atopic dermatitis by administering an il-4r antagonist
502014007297903/13/14Isolating cells expressing secreted proteins
512014007298003/13/14Isolating cells expressing secreted proteins
522014007301003/13/14Methods of modifying eukaryotic cells
532014007558603/13/14Parental cell lines for making cassette-free f1 progeny
542014005690302/27/14Human antibodies to gfr alpha 3 and methods of use thereof
552014005690702/27/14Anti-asic1 antibodies and uses thereof
562014004473002/13/14Anti-pcsk9 antibodies with ph-dependent binding characteristics
572014004106802/06/14Methods of modifying eukaryotic cells
582014003333601/30/14Methods of modifying eukaryotic cells
592014003333701/30/14Methods of modifying eukaryotic cells
602014002363701/23/14Methods of modifying eukaryotic cells
612014001722801/16/14Humanized light chain mice
622014001722901/16/14Methods of modifying eukaryotic cells
632014001723801/16/14Methods of modifying eukaryotic cells
642014001769501/16/14Isolating cells expressing secreted proteins
652014001778101/16/14Methods of modifying eukaryotic cells
662014001778201/16/14Methods for modifying eukaryotic cells
672014001852201/16/14Methods of modifying eukaryotic cells
682014002012401/16/14Methods of modifying eukaryotic cells
692014002012501/16/14Methods of modifying eukaryotic cells
702014001345601/09/14Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
712014001345701/09/14Methods of modifying eukaryotic cells
722013034453812/26/13Human antibodies to the glucagon receptor
732013034010412/19/13Humanized il-7 rodents
742013033305712/12/13Humanized non-human animals with restricted immunoglobulin heavy chain loci
752013032326012/05/13Stabilized formulations containing anti-dll4 antibodies
762013032326112/05/13Purified antibody composition
772013032378812/05/13Production cell line enhancers
782013032379012/05/13Human lambda light chain mice
792013032379112/05/13Restricted immunoglobulin heavy chain mice
802013032664712/05/13Human lambda light chain mice
812013030967011/21/13Nuclease-mediated targeting with large targeting vectors
822013031212811/21/13Promoter-regulated differentiation-dependent self-deleting cassette
832013031212911/21/13Promoter-regulated differentiation-dependent self-deleting cassette
842013029509711/07/13Human antibodies to fel d1 and methods of use thereof
852013028075810/24/13Fusion polypeptides capable of activating receptors
862013027307010/17/13Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor
872013026657410/10/13Human antibodies to human angiopoietin-like protein 4
882013025987610/03/13Anti-hla-b*27 antibodies and uses thereof
892013025988110/03/13Fusion polypeptides capable of activating receptors
902013026105610/03/13Vegf antagonist formulations
912013025172809/26/13Method of treating stress hyperglycemia with human antibodies to the glucagon receptor
922013025491109/26/13Adam6 mice
932013024377509/19/13Multispecific antigen-binding molecules and uses thereof
942013024378409/19/13Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
952013024723409/19/13Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
962013024723509/19/13Mice that produce antigen-binding proteins with ph-dependent binding characteristics
972013024723609/19/13Non-human animals expressing ph-sensitive immunoglobulin sequences
982013023053109/05/13Human antibodies to clostridium difficile toxins
992013023053309/05/13Methods of treating systemic lupus erythematosus (sle) using anti-cd48 antibodies
1002013021654708/22/13Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
1012013020949208/15/13Anti-tie2 antibodies and uses thereof
1022013021013708/15/13Methods of modifying eukaryotic cells
1032013021271908/15/13Humanized rodents that express heavy chain containing vl domains
1042013019587808/01/13Anti-asic1 antibodies and uses thereof
1052013019887908/01/13Humanized universal light chain mice
1062013019888008/01/13Mice expressing a limited immunoglobulin light chain repertoire
1072013018679707/25/13Stabilized formulations containing anti-ang2 antibodies
1082013018927707/25/13Stabilized formulations containing anti-pcsk9 antibodies
1092013018420507/18/13Antitumor combinations containing a vegf-inhibiting agent and 5fu or a derivative thereof
1102013018581907/18/13Genetically modified major histocompatibility complex animals
1112013018582007/18/13Genetically modified major histocompatibility complex animals
1122013018582107/18/13Common light chain mouse
1132013017114907/04/13Anti-angptl3 antibodies and uses thereof
1142013016478606/27/13Fucosylation-deficient cells
1152013015731306/20/13High affinity antibodies to human il-6 receptor
1162013016015306/20/13Humanized light chain mice
1172013014974406/13/13Methods for producing a fusion protein capable of binding vegf
1182013013710105/30/13Methods of modifying eukaryotic cells
1192013012972205/23/13Methods for treating cancer by administering an anti-ang-2 antibody
1202013012983005/23/13Polymer protein microparticles
1212013013037205/23/13Enhanced expression and stability regions
1222013013038805/23/13Methods of modifying eurakyotic cells
1232013012200305/16/13Methods of inhibiting tumor growth by antagonizing il-6 receptor
1242013012200705/16/13Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin a
1252013011787305/09/13Humanized il-6 and il-6 receptor
1262013010905305/02/13Genetically modified t cell receptor mice
1272013011161605/02/13Genetically modified major histocompatibility complex mice
1282013011161705/02/13Genetically modified major histocompatibility complex mice
1292013009556504/18/13Mirna-regulated differentiation-dependent self-deleting cassette
1302013009628704/18/13Restricted immunoglobulin heavy chain mice
1312013008429704/04/13Anti-erbb3 antibodies and uses thereof
1322013008463504/04/13Cell culture compositions capable of producing a vegf-binding fusion polypeptide
1332013008526604/04/13Anti-pcsk9 antibodies with ph-dependent binding characteristics
1342013007867503/28/13High affinity human antibodies to human il-4 receptor
1352013006483403/14/13Methods for treating hypercholesterolemia using antibodies to pcsk9
1362013004549202/21/13Methods for making fully human bispecific antibodies using a common light chain
1372013003490202/07/13Fusion polypeptides capable of activating receptors
1382013002889201/31/13Method of treating osteoarthritis with an antibody to ngf
1392012032210812/20/12Adam6 mice
1402012032349712/20/12Non-hypergeometric overlap probability
1412012025809810/11/12Method of treating rheumatoid arthritis with an anti-il-6r antibody
1422012026035710/11/12Low affinity fcgr deficient mice
1432012019589608/02/12Igf-1 fusion polypeptides and therapeutic uses thereof
1442012018963507/26/12Methods for treating or preventing malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
1452012019230007/26/12Common light chain mouse
1462012017868307/12/12Vegf antagonist formulations
1472012016468806/28/12High affinity human antibodies to human nerve growth factor
1482012013501005/31/12High affinity human antibodies to human il-4 receptor
1492012012867905/24/12Human antibodies to the glucagon receptor
1502012011464505/10/12Use of il-1 antagonists to treat pseudogout
1512012011465405/10/12Human antibodies to human tnf-like ligand 1a (tl1a)
1522012011466505/10/12Human antibodies to human rankl
1532012009756504/26/12Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
1542012010014504/26/12Methods for treating b-cell lymphoma by administering an anti-cd20 antibody
1552012010103504/26/12Vegf antagonist formulations
1562012009382404/19/12Methods for treating pruritus by administering an antibody that specifically binds human par2
1572012009657204/19/12Mice that make vl binding proteins
1582012008792904/12/12Vegf antagonist formulations for intravitreal administration
1592012008300004/05/12Neuropeptide release assay for sodium channels
1602012007679003/29/12Anti-cd48 antibodies and uses thereof
1612012007086103/22/12Human lambda light chain mice
1622012007300403/22/12Hybrid light chain mice
1632012006462103/15/12Cell culture compositions capable of producing a vegf-binding fusion polypeptide
1642012005207203/01/12High affinity human antibodies to human il-4 receptor
1652012004544002/23/12Method of treating rheumatoid arthritis with an anti-il-6r antibody
1662012002140901/26/12Common light chain mouse
1672012001496801/19/12Stabilized formulations containing anti-ngf antibodies
1682012000369701/05/12High affinity antibodies to human il-6 receptor
1692011031834212/29/11Methods of using il-1 antagonists to treat autoinflammatory disease
1702011031153712/22/11Methods of using il-1 antagonists to treat familial mediterranean fever (fmf)
1712011030796612/15/11Mice expressing human voltage-gated sodium channels
1722011030796812/15/11Production of fertile xy animals from xy es cells
1732011029363012/01/11Antibodies to human gdf8
1742011028337611/17/11Methods of modifying eukaryotic cells
1752011026918711/03/11High affinity human antibodies to human il-18 receptor
1762011025614810/20/11Methods for treating hypercholesterolemia using antibodies to pcsk9
1772011025655610/20/11Humanized fcgr mice
1782011025658710/20/11High affinity human antibodies to human nerve growth factor
1792011025760110/20/11Vegf antagonist formulations for intravitreal administration
1802011025871010/20/11Methods of modifying eukaryotic cells
1812011019545408/11/11Common light chain mouse
1822011018917608/04/11Methods of treating diseases with dll4 antagonists
1832011018920008/04/11Methods of treating autoimmune diseases with dll4 antagonists
1842011017124107/14/11Stabilized formulations containing anti-interleukin-6 (il-6) antibodies
1852011016565007/07/11Fusion polypeptides capable of activating receptors
1862011015901506/30/11Human antibodies to human angiopoietin-like protein 4
1872011015090506/23/11Human antibodies to human delta like ligand 4
1882011015451206/23/11Humanized fc gamma r mice
1892011014593706/16/11Mice that make heavy chain antibodies
1902011010479905/05/11Multifunctional alleles
1912011008168104/07/11Human antibodies to human cd20 and method of using thereof
1922011006590203/17/11High affinity human antibodies to pcsk9
1932011005909503/10/11High affinity human antibodies to human protease-activated receptor-2
1942011004119602/17/11Mirna-regulated differentiation-dependent self-deleting cassette
1952011004119702/17/11Promoter-regulated differentiation-dependent self-deleting cassette
1962011002728602/03/11High affinity human antibodies to human angiopoietin-2
1972011002034201/27/11Igf-1 fusion polypeptides and therapeutic uses thereof
1982011001420801/20/11Method of treating osteoarthritis with an antibody to ngf
1992011000837401/13/11Use of il-1 antagonists to treat gout
2002010033010612/30/10Method of treating cancer with dll4 antagonist and chemotherapeutic agent
2012010033152712/30/10Readily isolated bispecific antibodies with native immunoglobulin format
2022010031662712/16/10Human antibodies to human il-6 receptor
2032010031663612/16/10Method of treating rheumatoid arthritis with an il-6r antibody
2042010030443612/02/10Fucosylation-deficient cells
2052010029110711/18/10High affinity human antibodies to human il-4 receptor
2062010029162611/18/10Enhanced expression and stability regions
2072010027993311/04/10Vegf antagonist formulations
2082010023380309/16/10Fusion polypeptides capable of activating receptors
2092010022178209/02/10Modified chimeric polypeptides with improved pharmacokinetic properties
2102010016676807/01/10High affinity human antibodies to pcsk9
2112010012981705/27/10Identifying germline competent embryonic stem cells
2122010011192105/06/10Use of il-1 antagonists to treat gout
2132010008763204/08/10Vegf-binding fusion proteins and therapeutic uses thereof
2142010007590303/25/10Lyophilized vegf antagonist formulations for intravitreal administration
2152010004725402/25/10High affinity human antibodies to human il-4 receptor
2162010004233002/18/10Non-hypergeometric overlap probability
2172010003483302/11/10High affinity human antibodies to human il-18 receptor
2182010002147601/28/10High affinity human antibodies to human il-4 receptor
2192009028584111/19/09Antitumor combinations containing a vegf-inhibiting agent and 5fu or a derivative thereof
2202009027188410/29/09Es cell-derived mice from diploid host embryo injection
2212009024619910/01/09Therapeutic methods for inhibiting tumor growth with dll4 antagonists
2222009017586407/09/09Igf-1 and igf-2 chimeric polypeptides and therapeutic uses thereof
2232009016290106/25/09Inducible eukaryotic expression system
2242009015589906/18/09Modified chimeric polypeptides with improved pharmacokinetic properties
2252009015649206/18/09Methods of using il-1 antagonists to treat autoinflammatory disease
2262009014235406/04/09Human antibodies to human delta like ligand 4
2272009013741605/28/09Isolating cells expressing secreted proteins
2282009012344605/14/09Use of il-1 antagonists to treat gout
2292009012400505/14/09Enhanced expression and stability regions
2302009008121703/26/09Modified chimeric polypeptides with improved pharmacokinetic properties
2312009007479303/19/09High affinity human antibodies to human il-4 receptor
2322009006220003/05/09Vegf-binding fusion proteins and therapeutic uses thereof
2332009003532202/05/09Human antibodies to human cd20 and method of using thereof
2342013033305712/12/13Humanized non-human animals with restricted immunoglobulin heavy chain loci
2352010002147601/28/10High affinity human antibodies to human il-4 receptor


ARCHIVE: New 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Regeneron Pharmaceuticals, Inc. in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Regeneron Pharmaceuticals, Inc. with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE
  
         



Key IP Translations - Patent Translations